-
Prognostic Effect of Sarcopenia in Hepatocellular Carcinoma Patients Targeted with Interventional Therapy Combined with Immunotherapy and Targeted Therapy [Corrigendum] J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-03-14 Hongcai Yang, Tianhao Cong, Yingen Luo, Chao Yang, Jinrui Ren, Xiao Li
-
LncRNA MEG3 Reduces the Ratio of M2/M1 Macrophages Through the HuR/CCL5 Axis in Hepatocellular Carcinoma J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-03-11 Huamei Wei, Xianjian Wu, Lizheng Huang, Chen Long, Qi Lu, Zheng Huang, Yanyan Huang, Wenchuan Li, Jian Pu
Objective: Tumor-associated macrophages play a crucial role in the development of hepatocellular carcinoma (HCC). Our study aimed to investigate the relationship between long coding RNA (lncRNA) maternally expressed gene 3 (MEG3), RNA-binding protein human antigen R (HuR), and messenger RNA C–C motif chemokine 5 (CCL5) in the modulation of M1 and M2 macrophage polarization in HCC. Methods: To induce
-
A Hypoxia-Related miRNA-mRNA Signature for Predicting the Response and Prognosis of Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-03-12 Shaoqi Zong, Guokai Huang, Bo Pan, Shasha Zhao, Changquan Ling, Binbin Cheng
Purpose: Transcatheter arterial chemoembolization (TACE) is commonly used in the treatment of hepatocellular carcinoma (HCC). However, not all patients respond to this treatment. TACE typically leads to hypoxia in the tumor microenvironment. Therefore, we aimed to construct a prognostic model based on hypoxia-related differentially expressed microRNA (miRNAs) in hepatocellular carcinoma (HCC) and to
-
Machine Learning-Based Nomogram for Predicting Overall Survival in Elderly Patients with Cirrhotic Hepatocellular Carcinoma Undergoing Ablation Therapy J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-03-07 Wenying Qiao, Shugui Sheng, Junnan Li, Ronghua Jin, Caixia Hu
Purpose: The aim of the study is to identify and evaluate multifaceted factors impacting the survival of elderly cirrhotic HCC patients following ablation therapy, with the goal of constructing a nomogram to predict their 3-, 5-, and 8-year overall survival (OS). Patients and Methods: A retrospective analysis was conducted on 736 elderly cirrhotic HCC patients who underwent ablation therapy between
-
Construction and Validation of a Novel Nomogram Predicting Recurrence in Alpha-Fetoprotein-Negative Hepatocellular Carcinoma Post-Surgery Using an Innovative Liver Function-Nutrition-Inflammation-Immune (LFNII) Score: A Bicentric Investigation J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-03-06 Bo-Lun Zhang, Jia Liu, Guanghao Diao, Jianping Chang, Junshuai Xue, Zhen Huang, Hong Zhao, Lingxiang Yu, Jianqiang Cai
Purpose: We developed a nomogram based on the liver function, nutrition, inflammation, and immunity (LFNII) score to predict recurrence-free survival (RFS) post-resection in patients with hepatocellular carcinoma (HCC) exhibiting alpha-fetoprotein (AFP) negativity (AFP ≤ 20 ng/mL). Patients and Methods: Clinical data of 661 patients diagnosed with alpha-fetoprotein-negative hepatocellular carcinoma
-
Efficacy and Safety of HepaSphere Drug-Eluting Bead Transarterial Chemoembolization Combined with Hepatic Arterial Infusion Chemotherapy as the Second-Line Treatment in Advanced Hepatocellular Carcinoma J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-03-04 Baojiang Liu, Song Gao, Jianhai Guo, Fuxin Kou, Shaoxing Liu, Xin Zhang, Aiwei Feng, Xiaodong Wang, Guang Cao, Hui Chen, Peng Liu, Haifeng Xu, Qinzong Gao, Renjie Yang, Liang Xu, Xu Zhu
Purpose: Recently, hepatic arterial infusion chemotherapy (HAIC) has also gained popularity for hepatocellular carcinoma (HCC). Several studies have compared HAIC and Transarterial chemoembolization (TACE). However, comparisons between TACE plus HAIC and HAIC are rarely reported. Here, we evaluated the performance of HepaSphere DEB-TACE combined with HAIC (Hepa-HAIC) compared to HAIC in patients with
-
Efficacy and Safety of Conversion Surgery for Advanced Hepatocellular Carcinoma After Hepatic Arterial Infusion Chemotherapy J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-03-04 Wenxuan Li, Zhikai Zheng, Jiongliang Wang, Tianqing Wu, Juncheng Wang, Yangxun Pan, Jinbin Chen, Dandan Hu, Li Xu, Yaojun Zhang, Minshan Chen, Zhongguo Zhou
Purpose: The aim of this study was to investigate the efficacy and safety of conversion surgery for advanced hepatocellular carcinoma (HCC) after hepatic arterial infusion chemotherapy (HAIC). Patients and Methods: Data from 172 HCC patients treated at Sun Yat-sen University Cancer Center between January 2016 and June 2021 with effective assessment of HAIC treatment response were retrospectively analyzed
-
Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-03-04 Shadi Chamseddine, Michael LaPelusa, Lianchun Xiao, Yehia I Mohamed, Sunyoung S Lee, Zishuo Ian Hu, Rikita I Hatia, Manal Hassan, James C Yao, Dan G Duda, Saumil Datar, Hesham M Amin, Ahmed O Kaseb
Introduction: In this study, we explored the potential of plasma growth hormone (GH) as a prognostic biomarker in patients with advanced HCC treated with durvalumab plus tremelimumab (D+T). Methods: In this study, we included 16 patients with advanced HCC who received D+T at MD Anderson Cancer Center between 2022 and 2023 and had plasma GH measurements recorded before treatment. Plasma GH levels were
-
Biochemical Safety of SBRT to Multiple Intrahepatic Lesions for Hepatocellular Carcinoma J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-03-05 Jacob T Hall, Andrew M Moon, Michael Young, Xianming Tan, Rami Darawsheh, Flora Danquah, Joel E Tepper, Ted K Yanagihara
Background: We aim to better characterize stereotactic body radiation therapy (SBRT)-related hepatic biochemical toxicity in patients with multiple intrahepatic lesions from hepatocellular carcinoma (HCC). Methods: We conducted a retrospective analysis of patients with HCC who underwent SBRT for 2 or more synchronous or metachronous liver lesions. We collected patient characteristics and dosimetric
-
Multiple Machine-Learning Fusion Model Based on Gd-EOB-DTPA-Enhanced MRI and Aminotransferase-to-Platelet Ratio and Gamma-Glutamyl Transferase-to-Platelet Ratio to Predict Microvascular Invasion in Solitary Hepatocellular Carcinoma: A Multicenter Study J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-02-29 Fei Wang, Chun Yue Yan, Yuan Qin, Zheng Ming Wang, Dan Liu, Ying He, Ming Yang, Li Wen, Dong Zhang
Background: Currently, it is still confused whether preoperative aminotransferase-to-platelet ratio (APRI) and gamma-glutamyl transferase-to-platelet ratio (GPR) can predict microvascular invasion (MVI) in solitary hepatocellular carcinoma (HCC). We aimed to develop and validate a machine-learning integration model for predicting MVI using APRI, GPR and gadoxetic acid disodium (Gd-EOB-DTPA) enhanced
-
Risks and Clinical Predictors of Hepatocellular Carcinoma in Chinese Populations: A Real-World Study of 10,359 Patients in Six Medical Centers J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-02-27 Chenjun Huang, Xiao Xiao, Lin Tong, Zhiyuan Gao, Jun Ji, Lin Zhou, Ya Li, Lijuan Liu, Huijuan Feng, Meng Fang, Chunfang Gao
Purpose: Early detection of hepatocellular carcinoma (HCC) through surveillance could reduce this cancer-associated mortality. We aimed to develop and validate algorithms using panel serum biomarkers to identify HCC in a real-world multi-center study in China. Patients and Methods: A total of 10,359 eligible subjects, including HCCs and benign liver diseases (BLDs), were recruited from six Chinese
-
Atezolizumab Plus Bevacizumab Combined with Transarterial Embolization Plus Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with a Diameter >8 Cm: A Retrospective Study J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-02-26 Hongjie Cai, Song Chen, Zhiqiang Wu, Fan Wang, Shuangyan Tang, Ludan Chen, Wenbo Guo
Purpose: Local in combination with systemic therapy might be an option for patients with advanced unresectable hepatocellular carcinoma (uHCC). This study examined the clinical benefits and adverse events (AEs) of first-line transarterial embolization (TAE) and hepatic arterial infusion chemotherapy (HAIC) combined with atezolizumab (Atezo) and bevacizumab (Bev) in patients with uHCC of a diameter
-
A Deep Learning Model Combining Multimodal Factors to Predict the Overall Survival of Transarterial Chemoembolization J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-02-26 Zhongqi Sun, Xin Li, Hongwei Liang, Zhongxing Shi, Hongjia Ren
Background: To develop and validate an overall survival (OS) prediction model for transarterial chemoembolization (TACE). Methods: In this retrospective study, 301 patients with hepatocellular carcinoma (HCC) who received TACE from 2012 to 2015 were collected. The residual network was used to extract prognostic information from CT images, which was then combined with the clinical factors adjusted by
-
Single-Cell RNA Sequencing Revealed That the Enrichment of TPI1+ Malignant Hepatocytes Was Linked to HCC Metastasis and Immunosuppressive Microenvironment J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-02-22 Yuxin Liang, Deyuan Zhong, Qinyan Yang, Yuan Tang, Yingying Qin, Yuhao Su, Xiaolun Huang, Jin Shang
Background: Tumor metastasis is the leading cause of high mortality in hepatocellular carcinoma (HCC). The metastasis-related HCC microenvironment is characterized by high heterogeneity. Single-cell RNA sequencing (scRNA-seq) may aid in determining specific cell clusters involved in regulating the immune microenvironment of HCC. Methods: The scRNA-seq data of 10 HCC samples were collected from the
-
Systemic Drugs for Hepatocellular Carcinoma: What Do Recent Clinical Trials Reveal About Sequencing and the Emerging Complexities of Clinical Decisions? J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-02-19 Vera Himmelsbach, Christine Koch, Jörg Trojan, Fabian Finkelmeier
Abstract: Liver cancer was the fourth leading cause of cancer death in 2015 with increasing incidence between 1990 and 2015. Orthotopic liver transplantation, surgical resection and ablation comprise the only curative therapy options. However, due to the late manifestation of clinical symptoms, many patients present with intermediate or advanced disease, resulting in no curative treatment option being
-
Treatment Patterns and Recommendations for Improving the Management of Hepatocellular Carcinoma in Saudi Arabia J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-02-16 Ashwaq Alolyan, Kanan Alshammari, Mohammad Arabi, Ahmed Alshehri, Hamad Alsuhaibani, Fahad Ibnshamsah, Abdullah Alsharm, Mervat Mahrous, Adnan Al Zanbagi, Mazen Hassanain, Shouki Bazarbashi
Abstract: Hepatocellular carcinoma (HCC) is the sixth most common type of cancer in the world associated with high morbidity and mortality. Despite being a significant healthcare burden there is limited information on the unmet needs and current treatment practices for intermediate and advanced-stage HCC in Saudi Arabia. This article analyzes the gaps and provides expert consensus on the management
-
Effect of Different Liver Resection Modalities on the Prognosis of Patients with Hepatocellular Carcinoma on the Left Lateral Lobe [Response to Letter] J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-02-14 Jianwei Liu, Minmin Sun, Kunpeng Fang, Jie Wang, Bowen Ma, Li Song, Ting Liu, Ming Tang, Kui Wang, Yong Xia
Response to Letter in regards to Effect of Different Liver Resection Modalities on the Prognosis of Patients with Hepatocellular Carcinoma on the Left Lateral Lobe [Letter]
-
Lipid Metabolism as a Potential Target of Liver Cancer J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-02-14 Kangze Wu, Feizhuan Lin
Abstract: Hepatocellular carcinoma (HCC) stands as a severe malignant tumor with a profound impact on overall health, often accompanied by an unfavorable prognosis. Despite some advancements in the diagnosis and treatment of this disease, improving the prognosis of HCC remains a formidable challenge. It is noteworthy that lipid metabolism plays a pivotal role in the onset, development, and progression
-
The Index sAGP is Valuable for Distinguishing Atypical Hepatocellular Carcinoma from Atypical Benign Focal Hepatic Lesions J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-02-08 Qing-Qing Luo, Qiao-Nan Li, Dan Cai, Song Jiang, Shao-Song Liu, Mao-Sheng Liu, Cong Lv, Jin-Ke Wang, Kun-He Zhang, Ting Wang
Purpose: The differential diagnosis of atypical hepatocellular carcinoma (aHCC) and atypical benign focal hepatic lesions (aBFHL) usually depends on pathology. This study aimed to develop non-invasive approaches based on conventional blood indicators for the differential diagnosis of aHCC and aBFHL. Patients and Methods: Hospitalized patients with pathologically confirmed focal hepatic lesions and
-
Lymphocyte-to-C Reactive Protein Ratio is an Independent Predictor of Survival Benefits for Hepatocellular Carcinoma Patients Receiving Radiotherapy J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-02-08 Zhan Shi, Sihui Zhu, Yuncheng Jin, Liang Qi, Mingzhen Zhou, Ziyan Zhou, Juan Zhang, Baorui Liu, Jie Shen
Background: Stereotactic body radiotherapy (SBRT) has emerged as an alternative approach for patients with hepatocellular carcinoma (HCC), and we aim to find potential prognostic biomarkers for HCC patients who received SBRT. Methods: In this study, we retrospectively analyzed HCC patients who underwent SBRT in our institution from January 2018 to December 2022. The inflammatory parameters, along with
-
RAD21: A Key Transcriptional Regulator in the Development of Residual Liver Cancer J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-02-05 Jin-Shu Pang, Xiu-Mei Bai, Wei-Jun Wan, Tong Kang, Rong Wen, Li-Peng Li, Hai-Hui Yin, Chun-Miao Lu, Dong-Yue Wen, Yun He, Hong Yang
Objective: Thermal ablation is a commonly used therapy for hepatocellular carcinoma (HCC). Nevertheless, inadequate ablation can lead to the survival of residual HCC, potentially causing rapid progression. The underlying mechanisms for this remain unclear. This study explores the molecular mechanism responsible for the rapid progression of residual HCC. Methods: We established an animal model of inadequate
-
Development and Validation of a Prognostic Nomogram for Patients with AFP and DCP Double-Negative Hepatocellular Carcinoma After Local Ablation J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-02-03 Wenying Qiao, Jiashuo Li, Qi Wang, Ronghua Jin, Honghai Zhang
Purpose: Although alpha-fetoprotein (AFP) and des-gamma-carboxyprothrombin (DCP) have a certain predictive ability for the prognosis of hepatocellular carcinoma (HCC), there are still some cases of aggressive recurrence among patients with AFP and DCP double-negative HCC (DNHC) after local ablation. However, prediction models to forecast the prognosis of DNHC patients are still lacking. Thus, this
-
Immunotherapy Efficacy in Advanced Hepatocellular Carcinoma in a Diverse and Underserved Population in the United States J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-02-03 Fernand Bteich, Kush Desai, Chenxin Zhang, Anahat Kaur, Rachel A Levy, Lydia Bioh, Aaron Wang, Sharmin Sultana, Andreas Kaubisch, Milan Kinkhabwala, Sarah Bellemare, Shabnam Fidvi, Devaraju Kanmaniraja, Robert Berkenblit, Jee-Young Moon, Adebola Adedimeji, Clara Y Tow, Yvonne Saenger
Background: : Incidence of hepatocellular cancer (HCC) in the Bronx is 61% higher than the rest of New York State. Underserved populations are not well represented in clinical trials of immune checkpoint inhibitors (ICI). Methods: Demographics were tabulated for 194 patients treated with ICI at the Montefiore-Einstein Comprehensive Cancer Center (MECCC) between 2017 and 2022. Categorical variables
-
Development and Validation of a Novel Nomogram Integrated with Hypoxic and Lactate Metabolic Characteristics for Prognosis Prediction in Hepatocellular Carcinoma J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-02-02 Xun Qiu, Libin Dong, Kai Wang, Xinyang Zhong, Hanzhi Xu, Shengjun Xu, Haijun Guo, Xuyong Wei, Wei Chen, Xiao Xu
Background: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Accumulating evidence indicates that hypoxia and lactate metabolism play critical roles in tumor progression and therapeutic efficacy. This study aimed to construct a hypoxia- and lactate metabolism-related prognostic model (HLPM) to evaluate survival and treatment responses for HCC patients and
-
Prediction of Non-Transplantable Recurrence After Liver Resection for Solitary Hepatocellular Carcinoma J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-01-26 Chunhui Zhang, Yuqing Tao, Rui Yang, Yueqi Wang, Yanyan Yu, Yang Zhou
Purpose: Using a combination model of preoperative imaging and clinical factors to predict non-transplantable recurrence (NTR) after liver resection and assist solitary hepatocellular carcinoma (HCC) patients in the selection of early treatment options. Patients and Methods: A retrospective analysis was conducted on 253 solitary HCC patients who underwent radical resection and had preoperative MRI
-
A Longitudinal Study of AFP Trajectories and Clinical Outcomes in Intermediate-Stage Hepatocellular Carcinoma After Hepatectomy J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-01-25 Hongyi Yang, Linbin Lu, Wanting Guo, Baocuo Gong, Xuewen Wang, Yaying Chen, Xiong Chen
Background: Previous studies have shown that the alpha-fetoprotein (AFP) response has been a key tumour marker in hepatocellular carcinoma (HCC), but its definition remains controversial. Recently, a new study has explored and defined the AFP serological response and used it to explain the subclass of intermediate-stage hepatocellular carcinoma (IM-HCC) with “sharp-falling” AFP change after transarterial
-
Liver Injury and Its Impact on Prognosis in Patients with HBV-Related Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-01-24 Jiaming Shen, Xia Wang, Guangde Yang, Li Li, Juanjuan Fu, Wei Xu, Qingqiao Zhang, Xiucheng Pan
Purpose: Recently, the triple therapy of transarterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) plus immune checkpoint inhibitors (ICIs) has become a new treatment option for advanced or unresectable hepatocellular carcinoma (HCC) patients. We aimed to explore the liver injury and its effect on overall survival (OS) in patients treated with this combination therapy.
-
A Grading System of Microvascular Invasion for Patients with Hepatocellular Carcinoma Undergoing Liver Resection with Curative Intent: A Multicenter Study J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-01-24 Han Wang, Jun-Jie Chen, Shu-Yi Yin, Xia Sheng, Hong-Xia Wang, Wan Yee Lau, Hui Dong, Wen-Ming Cong
Background: Microvascular invasion (MVI) is closely correlated with poor clinical outcomes in patients with hepatocellular carcinoma (HCC). A grading system of MVI is needed to assist in the management of HCC patient. Methods: Multicenter data of HCC patients who underwent liver resection with curative intent was analyzed. This grading system was established by detected number and distance from tumor
-
Prognostic Effect of Sarcopenia in Hepatocellular Carcinoma Patients Targeted with Interventional Therapy Combined with Immunotherapy and Targeted Therapy J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-01-24 Hongcai Yang, Tianhao Cong, Yingen Luo, Chao Yang, Jinrui Ren, Xiao Li
Objective: To investigated the association between sarcopenia and the prognosis and adverse events of hepatocellular carcinoma (HCC) patients undergoing interventional therapy combined with immunotherapy and targeted therapy. Methods: Between January 2019 and December 2022, patients with unresectable HCC who received interventional therapy combined with immunotherapy and targeted therapy were included
-
Effect of Different Liver Resection Modalities on the Prognosis of Patients with Hepatocellular Carcinoma on the Left Lateral Lobe [Letter] J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-01-23 Changzhi Chen, Jieyun Cai, Ling Li
Letter for the article Effect of Different Liver Resection Modalities on the Prognosis of Patients with Hepatocellular Carcinoma on the Left Lateral Lobe
-
The Role of Type 2 Diabetes Mellitus–Related Risk Factors and Drugs in Hepatocellular Carcinoma J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-01-19 Yuhua Mai, Liheng Meng, Ganlu Deng, Yingfen Qin
Abstract: With changes in modern lifestyles, type 2 diabetes mellitus (T2DM) has become a global epidemic metabolic disease, and hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. T2DM is a complex metabolic disorder and has been considered an independent risk factor for HCC. Growing evidence supports that T2DM-related risk factors facilitate hepatocarcinogenesis
-
Monocyte-to-High-Density Lipoprotein-Cholesterol Ratio Predicts Prognosis of Hepatocellular Carcinoma in Patients with Metabolic-Associated Fatty Liver Disease J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-01-18 Tongguo Miao, Xianzhe Lou, Shiming Dong, Xiaoxiao Zhang, Weiwei Guan, Ying Zhang, Lu Li, Xiwei Yuan, Dong Ma, Yuemin Nan
Purpose: The incidence of non-B and non-C hepatocellular carcinoma (NBNC-HCC) is increasing globally. Metabolically associated fatty liver disease (MAFLD) has been a contributing factor to this rising trend in NBNC-HCC incidence. The monocyte-to-high-density lipoprotein-cholesterol ratio (MHR) is a new prognostic marker that connects systemic inflammation with disorders of lipid metabolism. Therefore
-
Serum Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) as a Potential Biomarker for Diagnosis of Hepatocellular Carcinoma J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-01-16 Ziran Wang, Lingjun Kong, Rui Zhang, Xiaobo Yang, Zhe Cao, Tengda Xu, Han Zhang, Yaling Dou
Objective: To evaluate the diagnostic performance of aldo-keto reductase family 1 member B10 (AKR1B10) in a Beijing cohort with hepatocellular carcinoma (HCC). Methods: This study included 521 subjects who visited Peking Union Medical College Hospital from June 2017 to May 2023, including 109 cases of HCC, 165 cases of healthy controls, 106 cases of benign liver diseases, and 141 cases of other cancers
-
Advances in Targeted Drug Resistance Associated with Dysregulation of Lipid Metabolism in Hepatocellular Carcinoma J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-01-16 Xiaoju Huang, Mengmeng Wang, Dan Zhang, Chen Zhang, Pian Liu
Abstract: Hepatocellular carcinoma is the prevailing malignant neoplasm affecting the liver, often diagnosed at an advanced stage and associated with an unfavorable overall prognosis. Sorafenib and Lenvatinib have emerged as first-line therapeutic drugs for advanced hepatocellular carcinoma, improving the prognosis for these patients. Nevertheless, the issue of tyrosine kinase inhibitor (TKI) resistance
-
The Role of GNMT and MMP12 Expression in Determining TACE Efficacy: Validation at Transcription and Protein Levels J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-01-17 Tianhao Cong, Chao Yang, Qi Cao, Jinrui Ren, Yingen Luo, Pei Yuan, Bo Zheng, Yu Liu, Hongcai Yang, Wendi Kang, Aixin Ou, Xiao Li
Purpose: Transarterial chemoembolization (TACE) represents a significant therapeutic modality for hepatocellular carcinoma (HCC). We aimed to develop a gene signature to accurately predict patient TACE response and explore the underlying mechanisms. Methods: Three independent datasets were utilized, including GSE104580, GSE14520 and external validation from the Cancer Hospital Chinese Academy of Medical
-
First-Line Treatment for Advanced Hepatocellular Carcinoma: A Three-Armed Real-World Comparison J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-01-13 Robert Mahn, Oscar André Glüer, Farsaneh Sadeghlar, Christian Möhring, Taotao Zhou, Thomas Anhalt, Malte Benedikt Monin, Alexander Kania, Tim R Glowka, Georg Feldmann, Peter Brossart, Joerg C Kalff, Ingo GH Schmidt-Wolf, Christian P Strassburg, Maria A Gonzalez-Carmona
Background and Aim: There are several existing systemic 1st- line therapies for advanced hepatocellular carcinoma (HCC), including atezolizumab/bevacizumab (Atez/Bev), sorafenib and lenvatinib. This study aims to compare the effectiveness of these three 1st-line systemic treatments in a real-world setting for HCC, focusing on specific patient subgroups analysis. Methods: A total of 177 patients with
-
Development and Validation of a Nomogram to Predict the Recurrence of HCC Patients Undergoing CECT After Ablation J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-01-13 Wenying Qiao, Zibo Fan, Qi Wang, Ronghua Jin, Caixia Hu
Purpose: We first aimed to compare the prognostic difference between the application of Contrast-enhanced computed tomography (CECT) and Non-enhanced computed tomography (NECT) in hepatocellular carcinoma(HCC) patients with early-stage immediately after ablation. We secondly propose to explore the risk factors for recurrence in patients undergoing CECT, and then develop a nomogram. Patients and Methods:
-
A Retrospective Study on Predicting Recurrence of Intermediate-Stage Hepatocellular Carcinoma After Radical Therapy J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-01-12 Ruyu Han, Leijuan Gan, Mengran Lang, Guangtao Li, Lu Chen, Xindi Tian, Kangwei Zhu, Liyu Sun, Tianqiang Song
Purpose: This study aimed to investigate the potential benefits of radical therapy in patients with stage B disease. Patients and Methods: A retrospective analysis was conducted on a cohort of 437 patients diagnosed with stage B hepatocellular carcinoma, who underwent either hepatic resection (HR) or radiofrequency ablation (RFA) at the Cancer Institute and Hospital of Tianjin Medical University from
-
Novel Preoperative Type IV Collagen to Predict the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Related Cirrhotic Portal Hypertension After Laparoscopic Splenectomy and Azygoportal Disconnection J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-01-12 Tian-Ming Gao, Sheng-Jie Jin, Fang Fang, Jian-Jun Qian, Chi Zhang, Bao-Huan Zhou, Dou-Sheng Bai, Guo-Qing Jiang
Purpose: Although laparoscopic splenectomy and azygoportal disconnection (LSD) can significantly decrease portal vein pressure and even the incidence of hepatocellular carcinoma (HCC) in patients with cirrhotic portal hypertension (CPH), postoperative HCC inevitably occurs in certain patients. The purpose of this study was to seek a novel preoperative non-invasive predictive indicator to predict the
-
PD1 and TIM3 Expression is Associated with Very Early Hepatocellular Carcinoma Recurrence After Percutaneous Thermal Ablation J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-01-09 Julien Ghelfi, Zuzana Macek Jilkova, Christian Sengel, Bleuenn Brusset, Yann Teyssier, Charlotte Costentin, Marion Mercey-Ressejac, Lucile Dumolard, Marc Manceau, Eliott Mathieu, Ivan Bricault, Thomas Decaens
Purpose: Percutaneous thermal ablation (PTA) is a cornerstone in the management of early-stage hepatocellular carcinoma (HCC). However, intrahepatic distant recurrence (IDR) occurs in the majority of patients after PTA. The aim of this study was to evaluate the immune signature associated with very early IDR. Patients and Methods: Thirty-one patients (26 men, 5 women; mean age:72.4 ± 8.6; age range:57–
-
Efficacy and Safety of Transarterial Chemoembolization Plus Donafenib with or without Immune Checkpoint Inhibitors as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-01-09 Liwei Deng, Yanyuan Sun, Haiqing Wang, Changli Liao, Deshan Li, Guohui Xu, Xuegang Yang
Purpose: To compare the efficacy and safety of transarterial chemoembolization (TACE) plus donafenib with immune checkpoint inhibitors (ICIs) (T+D+I) versus TACE plus donafenib (T+D) as the first-line treatment for patients with unresectable hepatocellular carcinoma (HCC). Methods: This retrospective study included patients with unresectable HCC who received T+D+I or T+D between June 2021 and February
-
An Engineered Influenza a Virus Expressing the Co-Stimulator OX40L as an Oncolytic Agent Against Hepatocellular Carcinoma J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-01-09 Hao Yang, Guanglin Lei, Zhuoya Deng, Fang Sun, Yuying Tian, Jinxia Cheng, Hongyu Yu, Cong Li, Changqing Bai, Shaogeng Zhang, Guangwen An, Penghui Yang
Background: Oncolytic virus (OV) therapy has emerged as a promising novel form of immunotherapy. Moreover, an increasing number of studies have shown that the therapeutic efficacy of OV can be further improved by arming OVs with immune-stimulating molecules. Methods: In this study, we used reverse genetics to produce a novel influenza A virus, termed IAV-OX40L, which contained the immune-stimulating
-
PRMT1 Integrates Immune Microenvironment and Fatty Acid Metabolism Response in Progression of Hepatocellular Carcinoma J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2024-01-06 Jia Yan, Ke xin Li, Lei Yu, Heng ye Yuan, Zhi min Zhao, Jing Lin, Chang Shan Wang
Background: Protein arginine methyltransferase (PRMT) family members have important roles in cancer processes. However, its functions in the regulation of cancer immunotherapy of hepatocellular carcinoma (HCC) are incompletely understood. This study aimed to investigate the roles of PRMT1 in HCC. Methods: Single-cell RNA sequencing (scRNA-seq) and clinicopathological data were obtained and used to
-
Pencil Beam Scanning Carbon Ion Radiotherapy for Hepatocellular Carcinoma J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2023-12-29 Wenna Zhang, Xin Cai, Jiayao Sun, Weiwei Wang, Jingfang Zhao, Qing Zhang, Guoliang Jiang, Zheng Wang
Purpose: Carbon ion radiotherapy (CIRT) has emerged as a promising treatment modality for hepatocellular carcinoma (HCC). However, evidence of using the pencil beam scanning (PBS) technique to treat moving liver tumors remains lacking. The present study investigated the efficacy and toxicity of PBS CIRT in patients with HCC. Methods: Between January 2016 and October 2021, 90 consecutive HCC patients
-
Deciphering the Divergent Gene Expression Landscapes of m6A/m5C/m1A Methylation Regulators in Hepatocellular Carcinoma Through Single-Cell and Bulk RNA Transcriptomic Analysis J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2023-12-28 Hang-Tsung Liu, Cheng-Shyuan Rau, Yueh-Wei Liu, Ting-Min Hsieh, Chun-Ying Huang, Peng-Chen Chien, Hui-Ping Lin, Chia-Jung Wu, Pei-Chin Chuang, Ching-Hua Hsieh
Introduction: RNA modifications mediated by the m6A, m1A, and m5C regulatory genes are crucial for the progression of malignancy. This study aimed to explore the expression of regulator genes for m6A/m5C/m1A methylation at the single-cell level and to validate their expression in cancerous and adjacent para-cancerous liver tissues of adult patients with HCC who underwent tumor resection. Methods: The
-
Pretreatment Non-Invasive Biomarkers as Predictors to Estimate Portal Vein Tumor Thrombosis (PVTT) Risk and Long-Term Survival in HBV-Related Hepatocellular Carcinoma Patients Without PVTT J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2023-12-28 Bang Liu, Jia Liu, Xuan Mei, Zhi-Qiang Zhang, Jian Fang, Li-Li Zhou, Jiao-Long Zheng, Hai-Yan Lin, Xiu-Ling Zhu, Dong-Liang Li
Background: PVTT is a hallmark of advanced hepatocellular carcinoma (HCC). We aim to explore the influence of non-invasive biomarkers on the occurrence of PVTT and develop and validate models for predicting prognosis in HBV-related HCC patients without PVTT. Methods: A total of 1026 HBV-related HCC patients without PVTT were enrolled, with 515 in the training cohort, 216 in the internal validation
-
Surgical Strategies Affect the Long-Term Prognosis of Patients with Hepatocellular Carcinoma Adjacent to the Left Branch of the Portal Vein J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2023-12-27 Shilei Bai, Xiaojing Shen, Jianwei Liu, Caixia Lu, Jie Wang, Liu Liu, Chunyan Wang, Huifeng Wang, Kai Liu, Yanfu Sun, Feng Xue
Purpose: When hepatocellular carcinoma (HCC) is closely associated with the left branch of the portal vein, there is still controversy regarding the surgical approach. Methods: This study enrolled 330 HCC patients with tumors adjacent to the left branch of the portal vein. Among them, 85 patients underwent left hemihepatectomy (LH), while the remaining 235 underwent liver lobectomy (LL), which included
-
Hepatitis B Virus-Encoded MicroRNA (HBV-miR-3) Inhibits FIH-1 Expression to Promote Tumor Angiogenesis in HBV-Related Hepatocellular Carcinoma J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2023-12-27 Han Chen, Dan Cao, Ning Han, Mingming Zhang, Wei Jiang, Xin Wang, Qinmin Zeng, Hong Tang
Introduction: Hepatocellular carcinoma (HCC) is a solid tumor with a rich blood supply, and anti-angiogenesis has important clinical significance. Hepatitis B Virus-Encoded MicroRNA 3 (HBV-miR-3) has recently been reported to be involved in HCC development. In this study, we aim to elucidate the role of HBV-miR-3 in promoting HBV-related HCC angiogenesis through Factor Inhibiting Hypoxia-inducible
-
Clinical-Radiological Characteristic for Predicting Ultra-Early Recurrence After Liver Resection in Solitary Hepatocellular Carcinoma Patients J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2023-12-21 Xinxin Wang, Yanyan Yu, Yuqing Tao, Yueqi Wang, Chunhui Zhang, Yali Cui, Yang Zhou
Objective: This study aims to identify independent risk factors for ultra-early recurrence in patients with early solitary hepatocellular carcinoma (HCC) and develop an individualized predictive nomogram for ultra-early recurrence. Materials and Methods: A total of 332 patients with early solitary HCC who underwent curative liver resection at our hospital from January 2015 to May 2021 were included
-
An Overview of Traditional Chinese Medicine in the Treatment After Radical Resection of Hepatocellular Carcinoma J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2023-12-18 Yichen Peng, Xia Wu, Yurong Zhang, Yue Yin, Xianglin Chen, Ding Zheng, Jing Wang
Abstract: According to the Barcelona Clinic Liver Cancer (BCLC) system, radical resection of early stage primary hepatocellular carcinoma (HCC) mainly includes liver transplantation, surgical resection, and radiofrequency ablation (RFA), which yield 5-year survival rates of about 70– 79%, 41.3– 69.5%, and 40– 70%, respectively. The tumor-free 5-year rate for HCC patients undergoing radical resection
-
Predicting T Cell-Inflamed Gene Expression Profile in Hepatocellular Carcinoma Based on Dynamic Contrast-Enhanced Ultrasound Radiomics J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2023-12-18 Yijie Wang, Weixiang Weng, Ruiming Liang, Qian Zhou, Hangtong Hu, Mingde Li, Lida Chen, Shuling Chen, Sui Peng, Ming Kuang, Han Xiao, Wei Wang
Purpose: The T cell-inflamed gene expression profile (GEP) quantifies 18 genes’ expression indicative of a T-cell immune tumor microenvironment, playing a crucial role in the immunotherapy of hepatocellular carcinoma (HCC). Our study aims to develop a radiomics-based machine learning model using contrast-enhanced ultrasound (CEUS) for predicting T cell-inflamed GEP in HCC. Methods: The primary cohort
-
Imaging-Derived Biomarkers Integrated with Clinical and Laboratory Values Predict Recurrence of Hepatocellular Carcinoma After Liver Transplantation J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2023-12-18 Thi Phuong Thao Hoang, Philipp Schindler, Nikolaus Börner, Max Masthoff, Mirjam Gerwing, Philippa von Beauvais, Enrico N De Toni, Christian M Lange, Jonel Trebicka, Haluk Morgül, Max Seidensticker, Jens Ricke, Andreas Pascher, Markus Guba, Michael Ingrisch, Moritz Wildgruber, Osman Öcal
Purpose: To investigate the prognostic value of computed tomography (CT) derived imaging biomarkers in hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT) and develop a predictive nomogram model. Patients and Methods: This retrospective study included 178 patients with histopathologically confirmed HCC who underwent liver transplantation between 2007 and 2021 at the two academic
-
Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2023-12-13 Benjian Gao, Fengyi Yang, Dongning Zheng, Shuai Hu, Jie Liu, Hong Liu, Yongfa Liu, LinXin Liu, Rui Wang, Yi Zhao, Cheng Cui, Cheng Fang, Jin Yang, Song Su, Yunwei Han, Xiaoli Yang, Bo Li
Purpose: This study aimed to explore the clinical efficacy of transarterial chemoembolization (TACE) in combination with tyrosine kinase inhibitors (TKIs) plus immune checkpoint inhibitors (ICIs) (triple therapy) compared to TACE alone (monotherapy) for advanced hepatocellular carcinoma (HCC). Material and Methods: Data of consecutive advanced HCC patients receiving triple therapy or monotherapy at
-
Survival Prediction Model for Patients with Hepatocellular Carcinoma and Extrahepatic Metastasis Based on XGBoost Algorithm J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2023-12-13 Jihye Lim, Hyeon-Gi Jeon, Yeonjoo Seo, Moonjin Kim, Ja Un Moon, Se Hyun Cho
Purpose: Accurate estimation of survival is of utmost importance in patients with hepatocellular carcinoma (HCC) and extrahepatic metastasis. This study aimed to develop a survival prediction model using real-world data. Patients and Methods: A total of 993 patients with treatment-naïve HCC and extrahepatic metastasis were included from 13 Korean hospitals between 2013 and 2018. Patients were randomly
-
Development and Validation of a Prognostic Model for Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma Based on Preoperative Serum Prealbumin J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2023-12-13 Lin Xu, Dongxu Zhao, Pengcheng Tian, Jiaan Ding, Zhengyu Jiang, Guanyin Ni, Zhongheng Hou, Caifang Ni
Purpose: We aimed to develop a prognostic nomogram utilizing preoperative serum prealbumin levels to predict the overall survival (OS) in patients undergoing transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC). Patients and Methods: A total of 768 individuals with unresectable HCC who underwent TACE at three medical facilities in Suzhou between January 2007 December
-
Nomogram for Estimation of Acute Liver Failure Risk in Spontaneous Ruptured Hepatocellular Carcinoma J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2023-12-12 Zhi-Hao Zhao, Chao Jiang, Qing-Yuan Wu, Guo-Yue Lv, Meng Wang
Purpose: Acute liver failure (ALF) is a severe complication of spontaneous ruptured hepatocellular carcinoma (SRHCC) that requires accurate prediction for effective treatment strategies. We aimed to develop a predictive nomogram to estimate the risk of ALF in patients with SRHCC undergoing treatment. Patients and Methods: We performed a retrospective analysis of historical data from 284 patients diagnosed
-
The Safety and Efficacy of Hepatic Arterial Infusion Chemotherapy Combined with PD-(L)1 Inhibitors and Molecular Targeted Therapies for the Treatment of Intermediate and Advanced Hepatocellular Carcinoma Unsuitable for Transarterial Chemoembolization J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2023-12-12 Hao-Huan Tang, Ming-Qing Zhang, Zi-Chen Zhang, Chen Fan, Yong Jin, Wei-Dong Wang
Objective: To investigate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with PD-(L)1 inhibitors and molecular targeted therapies (MTT) for intermediate and advanced HCC that are unsuitable for transarterial chemoembolization (TACE). Methods: We conducted a retrospective analysis of data from patients with TACE-unsuitable HCC who were receiving triple therapy from
-
Liver Regeneration-Related Genes of Nontumor Liver Tissues Predict the Prognosis of Patients with Hepatocellular Carcinoma J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2023-12-07 Yanchao Xu, Yunzheng Li, Yanjun Lu, Weihong Wang, Zhaowu Lian, Zijie Wu, Binghua Li, Decai Yu
Background: Hepatocellular carcinoma (HCC) is one of the most serious malignant tumors threatening human life with a high mortality rate. The liver regenerative capacity after hepatectomy in early-stage HCC patients is influenced by various factors, including surgical methods and energy metabolism. This study aims to provide a prognostic model based on genes related to liver regeneration that can predict
-
Implanting Iodine-125 Seed Strand Inside the Portal Vein Stent: An Improved Approach to Endovascular Brachytherapy for Treatment of Patients with Hepatocellular Carcinoma and Main Portal Vein Tumor Thrombus J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2023-12-06 Liang Zhang, Jun Wang, Yang Li, Leina Hou, Jianguo Xia, Jialin Shen
Purpose: To investigate the feasibility and efficacy of implanting an iodine-125 (125I) seed strand inside a portal vein stent (PVS) in the treatment of patients with hepatocellular carcinoma (HCC) and main portal vein tumor thrombus (mPVTT). Patients and Methods: Twenty-three patients who diagnosed with HCC and mPVTT and underwent endovascular implantation 125I seed strands and portal vein stenting
-
miR-612 Enhances RSL3-Induced Ferroptosis of Hepatocellular Carcinoma Cells via Mevalonate Pathway J. Hepatocell. Carcinoma (IF 4.1) Pub Date : 2023-12-06 Kailin Xing, Xinyu Bian, Dongmin Shi, Shuangshuang Dong, Hongxin Zhou, Shuxiu Xiao, Jinjin Bai, Weizhong Wu
Background: MicroRNA-612 (miR-612) has been proven to suppress the formation of invadopodia and inhibit hepatocellular carcinoma (HCC) metastasis by hydroxyacyl-CoA dehydrogenase alpha subunit (HADHA)-mediated lipid reprogramming. However, its biological roles in HCC cell ferroptosis remain unclear. Methods and Results: In this study, we found that HCC cells with high metastatic potential were more